Standard Biotools Inc (LAB) — Q3 2025 Revenue, Income Growth and Profitability Ratios Compared to Peers
Quarterly Revenue & Net Income Growth — Standard Biotools Inc vs Peers
Table 1: Revenue and net income growth for the 3 Months period, most recent quarter Q3 2025
| COMPANY NAME TICKER |
Period | REVENUE (Y/Y %) |
REVENUE (Q/Q %) |
INCOME (Y/Y %) |
INCOME (Q/Q %) |
|---|---|---|---|---|---|
| Standard Biotools Inc LAB |
Q3 2025 | -56.0% | -9.9% | - | - |
| Thermo Fisher Scientific Inc TMO |
Q3 2025 | 4.9% | 2.5% | -0.5% | 0.2% |
| Becton Dickinson And Company BDX |
Q3 2025 | 8.4% | 6.9% | 23.3% | -14.1% |
| Qiagen N v QGEN |
Q4 2024 | 1.0% | 1.0% | -75.5% | -75.5% |
| Agilent Technologies inc A |
Q2 2025 | 10.1% | 4.2% | 19.2% | 56.3% |
| Avantor Inc AVTR |
Q3 2025 | -5.3% | -3.5% | -1,331.5% | -1,200.2% |
| Illumina Inc ILMN |
Q3 2025 | 0.4% | 2.4% | -78.7% | -36.2% |
| Mettler Toledo International Inc MTD |
Q3 2025 | 7.9% | 4.7% | 2.8% | 7.5% |
| Bruker Corporation BRKR |
Q3 2025 | -0.4% | 8.0% | -245.2% | -1,492.9% |
| Revvity Inc RVTY |
Q3 2025 | 2.2% | -3.0% | -50.6% | -13.5% |
| Bio rad Laboratories Inc BIO |
Q3 2025 | 0.5% | 0.2% | -152.3% | -207.6% |
| Olink Holding Ab publ OLK |
Q4 2023 | 21.2% | 21.2% | 145.9% | 145.9% |
| 10x Genomics Inc TXG |
Q3 2025 | -2.0% | -13.8% | -23.2% | -179.5% |
| Cytek Biosciences Inc CTKB |
Q3 2025 | 11.0% | 25.3% | -47.5% | -52.0% |
| Quanterix Corporation QTRX |
Q3 2025 | 14.4% | 65.5% | 301.3% | 11.7% |
| Pacific Biosciences Of California Inc PACB |
Q3 2025 | -2.8% | -4.5% | -37.4% | -9.4% |
| Harvard Bioscience Inc HBIO |
Q3 2025 | -8.0% | 2.5% | -74.4% | -46.1% |
| Akoya Biosciences Inc AKYA |
Q1 2025 | -8.7% | -29.1% | -33.4% | 90.9% |
| Rapid Micro Biosystems Inc RPID |
Q3 2025 | 3.1% | 7.9% | -38.5% | -27.3% |
| Telesis Bio Inc TBIO |
Q3 2024 | -68.7% | 30.4% | -37.5% | -47.2% |
| Scientific Industries Inc SCND |
Q3 2025 | -49.3% | -39.7% | -438.5% | -362.3% |
| Reflect Scientific Inc RSCF |
Q2 2024 | 144.7% | 37.6% | -173.7% | -440.9% |
| Pressure Biosciences Inc PBIO |
Q2 2024 | -43.1% | 20.8% | 3.8% | -11.9% |
| Singular Genomics Systems Inc OMIC |
Q3 2024 | -12.1% | -44.9% | -24.9% | -21.0% |
| Astrotech Corp ASTC |
Q3 2025 | 773.5% | 35.0% | 5.7% | 18.3% |
| Nautilus Biotechnology Inc NAUT |
Q3 2025 | - | - | -17.5% | -9.7% |
| SUBTOTAL | Q3 2025 | 4.6% | 3.1% | -61.0% | -53.1% |
This table compares Standard Biotools Inc ’s quarterly revenue and net income growth to that of its corporate peers. It highlights how each company’s top-line and bottom-line performance changed during the most recent 3-month period Q3 2025. The first row displays Standard Biotools Inc ’s growth rates, followed by the performance of its peer group, allowing for a clear comparison of short-term momentum and operational trends across corporate peers. For more detailed financial information, analysis, and historical trends, simply click on any company name within the table to open its full comparison.
Growth rates are calculated using Y/Y and
Q/Q comparisons based on reported totals from the most recent
quarterly and annual filings submitted to the U.S. Securities and Exchange Commission (SEC).
All data is derived from CSIMarket.com’s
proprietary fundamentals database, which aggregates, standardizes, and normalizes structured XBRL filings.
Figures may be updated or restated following SEC amendments or revised issuer disclosures.
These tables include both corporate and publicly traded peers, allowing for a uniform
comparison of financial trends and short-term growth dynamics within the group.
For detailed company revenue growth rates, see
Revenue Growth Details, and for net income growth, see
Net Income Growth Details.
CSIMarket data powering this analysis is available across multiple delivery channels:
• Data Downloads (CSV / Excel)
• API & Programmatic Data Access
• Enterprise Data Licensing
• AI Training & Model Development License
• Marketplace Distribution Options
All CSIMarket datasets are designed for analytical workflows, financial modeling, academic research,
and AI/ML applications requiring normalized, reliable, and longitudinal financial time series.
Standard Biotools Inc 's Return on Assets, Investments and Equity, Receivables and Inventory Turnover vs Peers Comparison
Table 2: ROA, ROI And ROE based on Net Income for the 12 Months ended in Q3 2025, Inventory turnover based on costs of sale
| COMPANY NAME TICKER |
ROA (TTM %) |
ROI (TTM %) |
ROE (TTM %) |
RECEIVABLES TURNOVER (Ratio) |
INVENTORY TURNOVER (Ratio) |
|---|---|---|---|---|---|
|
Standard Biotools Inc LAB |
N/A | N/A | N/A | 5.34 | 2.05 |
| Thermo Fisher Scientific Inc TMO |
6.56% | 8.06% | 13.12% | 5.12 | 2.42 |
| Becton Dickinson And Company BDX |
3.07% | 3.90% | 6.52% | 7.96 | 3.26 |
| Qiagen N v QGEN |
1.47% | 1.70% | 2.34% | 5.50 | 3.41 |
| Agilent Technologies inc A |
12.11% | 14.40% | 23.85% | 5.02 | 2.97 |
| Avantor Inc AVTR |
-0.67% | N/A | N/A | 6.04 | 5.75 |
| Illumina Inc ILMN |
11.35% | 18.91% | 29.94% | 5.99 | 2.58 |
| Mettler Toledo International Inc MTD |
24.95% | 38.08% | N/A | 5.85 | 3.04 |
| Bruker Corporation BRKR |
-0.39% | N/A | N/A | 4.60 | 1.77 |
| Revvity Inc RVTY |
1.93% | 2.06% | 3.14% | 4.34 | 2.85 |
| Bio rad Laboratories Inc BIO |
-6.97% | N/A | N/A | 5.65 | 1.56 |
| Olink Holding Ab publ OLK |
-5.25% | N/A | N/A | 2.62 | N/A |
| 10x Genomics Inc TXG |
-2.22% | N/A | N/A | 7.18 | 2.62 |
| Cytek Biosciences Inc CTKB |
-1.28% | N/A | N/A | 3.60 | 1.96 |
| Quanterix Corporation QTRX |
-23.58% | N/A | N/A | 4.45 | 1.69 |
| Pacific Biosciences Of California Inc PACB |
-53.72% | N/A | N/A | 5.06 | 2.09 |
| Harvard Bioscience Inc HBIO |
-59.07% | N/A | N/A | 6.62 | 1.65 |
| Akoya Biosciences Inc AKYA |
-37.18% | N/A | N/A | 5.79 | 1.23 |
| Rapid Micro Biosystems Inc RPID |
-0.02% | N/A | N/A | 5.19 | 1.04 |
| Telesis Bio Inc TBIO |
-86.27% | N/A | N/A | 4.82 | 2.98 |
| Scientific Industries Inc SCND |
-54.95% | N/A | N/A | 8.84 | 1.41 |
| Reflect Scientific Inc RSCF |
-0.70% | N/A | N/A | 10.14 | 0.76 |
| Pressure Biosciences Inc PBIO |
-887.24% | N/A | N/A | 11.15 | 2.61 |
| Singular Genomics Systems Inc OMIC |
-37.90% | N/A | N/A | 8.05 | 0.31 |
| Astrotech Corp ASTC |
-51.64% | N/A | N/A | 3.10 | 1.85 |
| Nautilus Biotechnology Inc NAUT |
-28.41% | N/A | N/A | N/A | N/A |
| SUBTOTAL | 0.04% | 0.05% | 0.09% | 5.66 | 2.79 |
This table compares Standard Biotools Inc ’s profitability and efficiency ratios to those of its corporate peers. It shows how effectively each company generated returns on assets, investments, and equity over the 12-month period ending in Q3 2025, as well as how efficiently they managed receivables and inventory. The first row presents Standard Biotools Inc ’s ROA, ROI, ROE, receivables turnover, and inventory turnover, followed by the corresponding ratios for its peer group, enabling a clear comparison of long-term performance and operational efficiency within corporate Peers.
Methodology & Data Source:
Return on Assets, Return on Investments, Return on Equity, and turnover ratios are calculated using values reported in quarterly and annual financial statements filed with the U.S. Securities and Exchange Commission (SEC). All fundamental data used in these calculations is sourced from CSIMarket.com’s proprietary fundamentals database, which aggregates, standardizes, and normalizes structured XBRL filings across all reporting issuers. Figures may be updated or restated by companies following SEC amendments or revised disclosures.
For a detailed definition of Return on Investments (ROI), see
Return on Investments (ROI).
For Standard Biotools Inc ’s historical Return on Assets (ROA) performance, visit
ROA History.
Page last updated:
Data lineage: SEC Filings → XBRL Processing → CSIMarket Database → Growth Calculations.
For broader context and comparisons vs. Peers, visit
CSIMarket’s Company Overview for LAB Peers .
To download the tables, please subscribe.